Download presentation
Presentation is loading. Please wait.
Published byGriselda Allison Modified over 5 years ago
1
Leflunomide as adjuvant treatment of dermatomyositis
J. Scott Boswell, MD, Melissa I. Costner, MD Journal of the American Academy of Dermatology Volume 58, Issue 3, Pages (March 2008) DOI: /j.jaad Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions
2
Fig 1 A, Face and B, hands of patient 1 before treatment with leflunomide. Journal of the American Academy of Dermatology , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions
3
Fig 2 A, Face and B, hands of patient 1 after 1 year of treatment with leflunomide. Journal of the American Academy of Dermatology , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions
4
Fig 3 Timeline of systemic therapy for patients 1 to 3. AZA, Azathioprine; bid, twice a day; DM, dermatomyositis; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; PRED, prednisone; qd, 4 times a day; qw, q week; QUIN, quinacrine. Journal of the American Academy of Dermatology , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.